588 related articles for article (PubMed ID: 32603839)
1. Folic acid modified lipid-bilayer coated mesoporous silica nanoparticles co-loading paclitaxel and tanshinone IIA for the treatment of acute promyelocytic leukemia.
Li Z; Zhang Y; Zhu C; Guo T; Xia Q; Hou X; Liu W; Feng N
Int J Pharm; 2020 Aug; 586():119576. PubMed ID: 32603839
[TBL] [Abstract][Full Text] [Related]
2. Biotinylated-lipid bilayer coated mesoporous silica nanoparticles for improving the bioavailability and anti-leukaemia activity of Tanshinone IIA.
Li Z; Zhang Y; Zhang K; Wu Z; Feng N
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):578-587. PubMed ID: 29374971
[TBL] [Abstract][Full Text] [Related]
3. Co-delivery of paclitaxel (PTX) and docosahexaenoic acid (DHA) by targeting lipid nanoemulsions for cancer therapy.
Li B; Tan T; Chu W; Zhang Y; Ye Y; Wang S; Qin Y; Tang J; Cao X
Drug Deliv; 2022 Dec; 29(1):75-88. PubMed ID: 34964421
[TBL] [Abstract][Full Text] [Related]
4. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
[TBL] [Abstract][Full Text] [Related]
5. Thermo- and pH-responsive targeted lipid-coated mesoporous nano silica platform for dual delivery of paclitaxel and gemcitabine to overcome HER2-positive breast cancer.
Nasri N; Saharkhiz S; Dini G; Yousefnia S
Int J Pharm; 2023 Dec; 648():123606. PubMed ID: 37972671
[TBL] [Abstract][Full Text] [Related]
6. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
7. Lipid/PAA-coated mesoporous silica nanoparticles for dual-pH-responsive codelivery of arsenic trioxide/paclitaxel against breast cancer cells.
Zhang BB; Chen XJ; Fan XD; Zhu JJ; Wei YH; Zheng HS; Zheng HY; Wang BH; Piao JG; Li FZ
Acta Pharmacol Sin; 2021 May; 42(5):832-842. PubMed ID: 33824461
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein-Inspired Nanocarrier Composed of Folic Acid-Modified Protein and Lipids: Preparation and Evaluation of Tumor-Targeting Effect.
Han M; Ji X; Li J; Ge Z; Luo B; Zhou K; Wang Q; Sun X; Zhang W; Li J
Int J Nanomedicine; 2020; 15():3433-3445. PubMed ID: 32523342
[TBL] [Abstract][Full Text] [Related]
9. Folic Acid and Poly(ethylene glycol) Decorated Paclitaxel Nanocrystals Exhibit Enhanced Stability and Breast Cancer-Targeting Capability.
Zhao J; Du J; Wang J; An N; Zhou K; Hu X; Dong Z; Liu Y
ACS Appl Mater Interfaces; 2021 Mar; 13(12):14577-14586. PubMed ID: 33728919
[TBL] [Abstract][Full Text] [Related]
10. Tumor-targeting and pH-sensitive lipoprotein-mimic nanocarrier for targeted intracellular delivery of paclitaxel.
Chen C; Hu H; Qiao M; Zhao X; Wang Y; Chen K; Guo X; Chen D
Int J Pharm; 2015 Mar; 480(1-2):116-27. PubMed ID: 25615984
[TBL] [Abstract][Full Text] [Related]
11. PEGylated Lipid bilayer coated mesoporous silica nanoparticles for co-delivery of paclitaxel and curcumin: Design, characterization and its cytotoxic effect.
Lin J; Cai Q; Tang Y; Xu Y; Wang Q; Li T; Xu H; Wang S; Fan K; Liu Z; Jin Y; Lin D
Int J Pharm; 2018 Jan; 536(1):272-282. PubMed ID: 29079221
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel/IR1061-Co-Loaded Protein Nanoparticle for Tumor-Targeted and pH/NIR-II-Triggered Synergistic Photothermal-Chemotherapy.
He L; Qing F; Li M; Lan D
Int J Nanomedicine; 2020; 15():2337-2349. PubMed ID: 32308385
[TBL] [Abstract][Full Text] [Related]
13. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
[TBL] [Abstract][Full Text] [Related]
14. PEGylated lipid bilayer coated mesoporous silica nanoparticles co-delivery of paclitaxel and curcumin leads to increased tumor site drug accumulation and reduced tumor burden.
Gao J; Fan K; Jin Y; Zhao L; Wang Q; Tang Y; Xu H; Liu Z; Wang S; Lin J; Lin D
Eur J Pharm Sci; 2019 Dec; 140():105070. PubMed ID: 31518679
[TBL] [Abstract][Full Text] [Related]
15. Hemocompatibility of folic-acid-conjugated amphiphilic PEG-PLGA copolymer nanoparticles for co-delivery of cisplatin and paclitaxel: treatment effects for non-small-cell lung cancer.
He Z; Shi Z; Sun W; Ma J; Xia J; Zhang X; Chen W; Huang J
Tumour Biol; 2016 Jun; 37(6):7809-21. PubMed ID: 26695149
[TBL] [Abstract][Full Text] [Related]
16. Fabrication and in vivo evaluation of ligand appended paclitaxel and artemether loaded lipid nanoparticulate systems for the treatment of NSCLC: A nanoparticle assisted combination oncotherapy.
Khatri H; Chokshi N; Rawal S; Patel BM; Badanthadka M; Patel MM
Int J Pharm; 2020 Jun; 583():119386. PubMed ID: 32376440
[TBL] [Abstract][Full Text] [Related]
17. Folate-modified lipid-polymer hybrid nanoparticles for targeted paclitaxel delivery.
Zhang L; Zhu D; Dong X; Sun H; Song C; Wang C; Kong D
Int J Nanomedicine; 2015; 10():2101-14. PubMed ID: 25844039
[TBL] [Abstract][Full Text] [Related]
18. Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo.
Yao S; Li L; Su XT; Wang K; Lu ZJ; Yuan CZ; Feng JB; Yan S; Kong BH; Song K
J Exp Clin Cancer Res; 2018 Feb; 37(1):29. PubMed ID: 29478415
[TBL] [Abstract][Full Text] [Related]
19. Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo.
Wang W; Xi M; Duan X; Wang Y; Kong F
Int J Nanomedicine; 2015; 10():3737-50. PubMed ID: 26045664
[TBL] [Abstract][Full Text] [Related]
20. Novel lipid-coated mesoporous silica nanoparticles loaded with thymoquinone formulation to increase its bioavailability in the brain and organs of Wistar rats.
Fahmy HM; Ahmed MM; Mohamed AS; Shams-Eldin E; Abd El-Daim TM; El-Feky AS; Mustafa AB; Abd Alrahman MW; Mohammed FF; Fathy MM
BMC Pharmacol Toxicol; 2022 Sep; 23(1):71. PubMed ID: 36163187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]